Atazanavir
- Atc Codes:J05AE08
- CAS Codes:229975-97-7#198904-31-3
- PHARMGKB ID:229975-97-7#198904-31-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Reyataz; Belgium: Reyataz; Bulgaria: Reyataz; Cyprus: Reyataz; Czech Republic: Reyataz; Denmark: Reyataz; Estonia: Reyataz; Finland: Reyataz; France: Reyataz; Germany: Reyataz; Greece: Reyataz; Hungary: Reyataz; Ireland: Reyataz; Italy: Reyataz; Latvia: Reyataz; Lithuania: Reyataz; Luxembourg: Reyataz; Malta: Reyataz; Netherlands: Reyataz; Poland: Reyataz; Portugal: Reyataz; Romania: Reyataz; Slovakia: Reyataz; Slovenia: Reyataz; Spain: Reyataz; Sweden: Reyataz; UK: Reyataz.
North America
Canada: Reyataz; USA: Reyataz.
Latin America
Argentina: Reyataz; Brazil: Reyataz; Mexico: Reyataz.
Asia
Japan: Reyataz.
Drug combinations
Chemistry
Atazanavir Sulfate: C~38~H~52~N~6~O~7~ H~2~O~4~S. Mw: 802.93. (1) 2,5,6,10,13-Pentaazatetradecanedioic acid, 3-12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[-4-(2-pyridinyl)phenyl]methyl]-, dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1); (2) Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate, sulfate (1:1). CAS-229975-97-7; CAS-198904-31-3 (atazanavir)(2002).
Pharmacologic Category
Antiretrovirals; HIV Protease Inhibitors. (ATC-Code: J05AE08).
Mechanism of action
Inhibits HIV-1 protease.
Therapeutic use
Treatment of HIV-1 infections.
Pregnancy and lactiation implications
Not recommended for use during pregnancy (increased risk of hyperglycemia). Contraindicated during lactation.
Unlabeled use
Contraindications
Hypersensitivity to atazanavir or any component of the formulation. Concurrent therapy with cisapride, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), indinavir, irinotecan, lovastatin, midazolam, pimozide, rifampin, simvastatin, St. John’s wort, or triazolam.
Warnings and precautions
Asymptomatic elevations in bilirubin (unconjugated) occur commonly. May cause fat redistribution. May cause hypersensitivity events (rash, anaphylaxis, angioedema, bronchospasm, erythema multiforme, and/or Stevens-Johnson syndrome). Risk of developing immune reconstitution syndrome. Nephrolithiasis may occur. May prolong PR interval and rarely cause second degree AV block. Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, diabetic ketoacidosis, and new-onset diabetes mellitus might occur. Use with caution in hemophilia A or B (increased bleeding). May cause hepatic impairment. Contraindicated with drugs that are major CYP3A4 or UGT1A1 substrates.